Published by Duncan Ferris on 21st March 2019
(Sharecast News) - Biogen shares plummeted on Thursday after the company confirmed that it will cease clinical trials for aducanumab, the experimental Alzheimer's disease treatment it developed alongside its Nikkei 225-listed Japanese partner Eisai.
URL: http://www.digitallook.com/dl/news/story/28795470/...